Stock Scorecard
Stock Summary for NRX Pharmaceuticals Inc (NRXP) - $1.84 as of 2/20/2026 1:47:00 PM EST
Total Score
6 out of 30
Safety Score
19 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NRXP
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NRXP
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NRXP
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NRXP
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NRXP (19 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for NRXP
Financial Details for NRXP
Company Overview |
|
|---|---|
| Ticker | NRXP |
| Company Name | NRX Pharmaceuticals Inc |
| Country | USA |
| Description | NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/13/2026 |
Stock Price History |
|
| Last Day Price | 1.84 |
| Price 4 Years Ago | 11.10 |
| Last Day Price Updated | 2/20/2026 1:47:00 PM EST |
| Last Day Volume | 680,513 |
| Average Daily Volume | 1,336,347 |
| 52-Week High | 3.84 |
| 52-Week Low | 1.58 |
| Last Price to 52 Week Low | 16.46% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 18.63 |
| Sector PE | 148.47 |
| 5-Year Average PE | -6.52 |
| Free Cash Flow Ratio | 7.67 |
| Industry Free Cash Flow Ratio | 12.36 |
| Sector Free Cash Flow Ratio | 31.12 |
| Current Ratio Most Recent Quarter | 0.29 |
| Total Cash Per Share | 0.24 |
| Book Value Per Share Most Recent Quarter | -0.93 |
| Price to Book Ratio | 2.90 |
| Industry Price to Book Ratio | 3.36 |
| Sector Price to Book Ratio | 33.63 |
| Price to Sales Ratio Twelve Trailing Months | 225.10 |
| Industry Price to Sales Ratio Twelve Trailing Months | 47.64 |
| Sector Price to Sales Ratio Twelve Trailing Months | 23.44 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 29,605,200 |
| Market Capitalization | 54,473,568 |
| Institutional Ownership | 28.10% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 16.66% |
| Reported EPS 12 Trailing Months | -2.31 |
| Reported EPS Past Year | -1.59 |
| Reported EPS Prior Year | -2.33 |
| Net Income Twelve Trailing Months | -38,061,000 |
| Net Income Past Year | -25,126,000 |
| Net Income Prior Year | -30,150,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -54.44% |
| Operating Margin Twelve Trailing Months | -1,702.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,184,000 |
| Total Cash Past Year | 1,443,000 |
| Total Cash Prior Year | 4,595,000 |
| Net Cash Position Most Recent Quarter | 2,173,000 |
| Net Cash Position Past Year | -3,568,000 |
| Long Term Debt Past Year | 5,011,000 |
| Long Term Debt Prior Year | 10,525,000 |
| Total Debt Most Recent Quarter | 5,011,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -23,223,000 |
| Total Stockholder Equity Prior Year | -11,733,000 |
| Total Stockholder Equity Most Recent Quarter | -25,755,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -12,497,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.42 |
| Free Cash Flow Past Year | -10,637,000 |
| Free Cash Flow Prior Year | -21,660,000 |
Options |
|
| Put/Call Ratio | 0.02 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.13 |
| MACD Signal | -0.12 |
| 20-Day Bollinger Lower Band | 1.57 |
| 20-Day Bollinger Middle Band | 2.42 |
| 20-Day Bollinger Upper Band | 3.27 |
| Beta | 1.96 |
| RSI | 37.80 |
| 50-Day SMA | 2.58 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 2/21/2026 4:22:02 AM EST |